152 related articles for article (PubMed ID: 9189175)
1. Glycophorin A as a biological dosimeter for radiation dose to the bone marrow from iodine-131.
Jensen RH; Reynolds JC; Robbins J; Bigbee WL; Grant SG; Langlois RG; Pineda JD; Lee T; Barker WC
Radiat Res; 1997 Jun; 147(6):747-52. PubMed ID: 9189175
[TBL] [Abstract][Full Text] [Related]
2. The effects of dialysis on 131I kinetics and dosimetry in thyroid cancer patients--a pharmacokinetic model.
Pahlka RB; Sonnad JR
Health Phys; 2006 Sep; 91(3):227-37. PubMed ID: 16891898
[TBL] [Abstract][Full Text] [Related]
3. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
[TBL] [Abstract][Full Text] [Related]
4. Biological dosimetry in patients treated with iodine-131 for differentiated thyroid carcinoma.
M'Kacher R; Legal JD; Schlumberger M; Voisin P; Aubert B; Gaillard N; Parmentier C
J Nucl Med; 1996 Nov; 37(11):1860-4. PubMed ID: 8917193
[TBL] [Abstract][Full Text] [Related]
5. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
7. Hospital discharge of patients with thyroid carcinoma treated with 131I.
Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
[TBL] [Abstract][Full Text] [Related]
8. Radiation safety protocol for high dose 131I therapy of thyroid carcinoma in patients on hemodialysis for chronic renal failure.
Modarresifar H; Almodovar S; Bass WB; Ojha B
Health Phys; 2007 Feb; 92(2 Suppl):S45-9. PubMed ID: 17228187
[TBL] [Abstract][Full Text] [Related]
9. Elevated frequency of glycophorin A mutations in erythrocytes from Chernobyl accident victims.
Jensen RH; Langlois RG; Bigbee WL; Grant SG; Moore D; Pilinskaya M; Vorobtsova I; Pleshanov P
Radiat Res; 1995 Feb; 141(2):129-35. PubMed ID: 7838951
[TBL] [Abstract][Full Text] [Related]
10. [Dosimetry of the hematopoietic system in radioiodine therapy of thyroid cancer].
Günter HH; Junker D; Schober O; Hundeshagen H
Strahlenther Onkol; 1987 Mar; 163(3):185-91. PubMed ID: 3563879
[TBL] [Abstract][Full Text] [Related]
11. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
12. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
[TBL] [Abstract][Full Text] [Related]
13. Radiation dose to the upper spine from therapeutic administrations of iodine-131-sodium iodide.
Stabin MG
J Nucl Med; 1993 Apr; 34(4):695-6. PubMed ID: 8455090
[TBL] [Abstract][Full Text] [Related]
14. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?
de Carvalho JW; Sapienza M; Ono C; Watanabe T; Guimarães MI; Gutterres R; Marechal MH; Buchpiguel C
Nucl Med Commun; 2009 Jul; 30(7):533-41. PubMed ID: 19436231
[TBL] [Abstract][Full Text] [Related]
15. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA
J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014
[TBL] [Abstract][Full Text] [Related]
16. Radiotoxicity after iodine-131 therapy for thyroid cancer using the micronucleus assay.
Watanabe N; Yokoyama K; Kinuya S; Shuke N; Shimizu M; Futatsuya R; Michigishi T; Tonami N; Seto H; Goodwin DA
J Nucl Med; 1998 Mar; 39(3):436-40. PubMed ID: 9529288
[TBL] [Abstract][Full Text] [Related]
17. Chromosome aberrations after treatment with radioactive iodine for thyroid cancer.
Baugnet-Mahieu L; Lemaire M; Léonard ED; Léonard A; Gerber GB
Radiat Res; 1994 Dec; 140(3):429-31. PubMed ID: 7972697
[TBL] [Abstract][Full Text] [Related]
18. [Long-term hematologic changes caused by radioiodine treatment of thyroid cancer. II. Bone marrow changes including leukemia].
Günter HH; Schober O; Schwarzrock R; Hundeshagen H
Strahlenther Onkol; 1987 Jul; 163(7):475-85. PubMed ID: 3616906
[TBL] [Abstract][Full Text] [Related]
19. [Bone marrow depression due to 131I treatment of thyroid cancer].
Keldsen N; Mortensen BT; Hansen HS
Ugeskr Laeger; 1988 Nov; 150(46):2817-9. PubMed ID: 3206692
[No Abstract] [Full Text] [Related]
20. Dose response for T-cell receptor (TCR) mutants in patients repeatedly treated with 131I for thyroid cancer.
Vershenya S; Biko J; Drozd V; Lorenz R; Reiners C; Hempel K
Mutat Res; 2004 Apr; 548(1-2):27-33. PubMed ID: 15063133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
